Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEH1 | O60930 | 2/20 | 0.54 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.41 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13728919 | 0.86 | CATSPER1 (0.41) | RNASEH1EGLN1NR1H2NR1H3CHUK | |
| SCHEMBL13729492 | 0.84 | CALM1 (0.46) | RNASEH1CHUKTXNRD1NOX4ALDH1A1 | |
| SCHEMBL5128630 | 0.83 | RNASEH1 (0.59) | RNASEH1EGLN1NR1H2NR1H3ALDH1A1 | |
| SCHEMBL5127890 | 0.82 | EGLN1 (0.52) | EGLN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15458815 | 0.80 | EGLN1 (0.43) | RNASEH1EGLN1ALDH1A1MAPT | |
| SCHEMBL15458802 | 0.79 | EGLN1 (0.56) | RNASEH1EGLN1PTPN1PTPN2PTPN6 | |
| SCHEMBL15458875 | 0.78 | P2RX3 (0.47) | RNASEH1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5129033 | 0.76 | ALDH1A1 (0.50) | EGLN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL15458869 | 0.76 | EGLN1 (0.47) | RNASEH1EGLN1SMN1; SMN2 | |
| SCHEMBL5128898 | 0.74 | CALCA (0.50) | EGLN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329842-A1 | SMALL MOLECULE COMPOUNDS AS BROAD-SPECTRUM INHIBITORS OF METALLO-BETA-LACTAMASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-12-27 | — | — | US | disclosed |
| US-20120329842-A1 | SMALL MOLECULE COMPOUNDS AS BROAD-SPECTRUM INHIBITORS OF METALLO-BETA-LACTAMASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-12-27 | — | — | US | disclosed |
| WO-2012088283-A1 | SMALL MOLECULE COMPOUNDS AS BROAD-SPECTRUM INHIBITORS OF METALLO-BETA-LACTAMASES | BAYLOR COLLEGE OF MEDICINE (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329842-A1 | SMALL MOLECULE COMPOUNDS AS BROAD-SPECTRUM INHIBITORS OF METALLO-BETA-LACTAMASES | MGAM, MGAM2, BPGM | RNASEH1 643/4885EGLN1 3399/4885NR1H2 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.